Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Meta-Analysis

The Prognostic Value of Long Non-Coding RNA SNHG7 in Human Cancer: A Meta-Analysis

Author(s): Kexun Yu, Weijie Yuan, Changhao Huang, Lei Xiao, Runsha Xiao, Pengwei Zeng, Lu Chen* and Zihua Chen*

Volume 23, Issue 7, 2022

Published on: 10 August, 2021

Page: [946 - 958] Pages: 13

DOI: 10.2174/1389201022666210810100607

Price: $65

Abstract

Background: The long non-coding RNA SNHG7 is upregulated in many types of cancer and plays a role as an oncogene. However, its overall predictive ability in human cancer prognosis has not been assessed using existing databases. Therefore, further study of its prognostic value and clinical significance in human malignancies is warranted.

Methods: We systematically collected relevant literature from multiple electronic document databases about the relationship between SNHG7 expression level and prognosis in patients with solid cancers. We further screenped them for eligibility. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value. Odds ratios (ORs) and their 95% CIs were collected to evaluate the relationship between the expression of SNHG7 and clinicopathological features, including lymph node metastasis (LNM), tumour size, tumour node metastasis (TNM) stage and histological grade.

Results: Fourteen original studies involving 971 patients were enrolled strictly following the inclusion and exclusion criteria. The meta-analysis showed that SNHG7 expression significantly correlated with poor overall survival (HR = 1.93, 95% CI: 1.64–2.26, p<0.001) in human cancer patients. In addition, the pooled OR indicated that overexpression of SNHG7 was associated with earlier LNM (OR = 1.83, 95% CI: 1.44–2.32; P <0.001), and advanced TNM stage (OR = 1.82, 95% CI: 1.44–2.30; P <0.001). Meanwhile, there was no significant heterogeneity between the selected studies, proving the reliability of the meta-analysis results.

Conclusion: High SNHG7 expression may predict poor oncological outcomes in patients with multiple human cancers, which could be a novel prognostic biomarker of unfulfilled clinicopathological features. However, further high-quality studies are needed to verify and strengthen the clinical value of SNHG7 in different types of cancer.

Keywords: Long non-coding RNA, cancer, prognosis, SNHG7, clinicopathological characteristics, meta-analysis.

Graphical Abstract
[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. clinicians JAJCacjf: Cancer statistics 2018, 68(1), 7-30.
[2]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. cancer BFJIjo: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[3]
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China. CA Cancer J.Clin.,2015 2016, 66(2), 115-132.
[4]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2017, 67(1), 7-30.
[5]
Miller, K.D.; Siegel, R.L.; Lin, C.C.; Mariotto, A.B.; Kramer, J.L.; Rowland, J.H.; Stein, K.D.; Alteri, R.; Jemal, A. clinicians JAJCacjf: Cancer treatment and survivorship statistics. CA Cancer J. Clin., 2016, 66(4), 271-289.
[6]
Li, W.; Wang, D.; Sun, X.; Zhang, Y.; Wang, L.; Suo, J. Surgery ZZJAo: Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Int. J. Mol. Med., 2012, 256(6), 1014-1022.
[7]
Feng, L.; Li, J.; Li, F.; Li, H.; Bei, S.; Zhang, X.; Yang, Z. Long noncoding RNA VCAN-AS1 contributes to the progression of gastric cancer via regulating p53 expression. J. Cell. Physiol., 2020, 235(5), 4388-4398.
[http://dx.doi.org/10.1002/jcp.29315] [PMID: 31637706]
[8]
AH, W.; WJ, F.; L, F. medical WXJErf, sciences p: LncRNA PCAT- 1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. 2019, 23(19), 8310- 8320..
[9]
Tuck, A.C.; Tollervey, D. A Transcriptome-wide atlas of rnp composition reveals diverse classes of MRNAs and LncRNAs. Cell, 2013, 154(5), 996-1009.
[http://dx.doi.org/10.1016/j.cell.2013.07.047]]
[10]
Zhang, H.; Wang, Y.; Liu, X.; Li, Y. Progress of long noncoding RNAs in anti-tumor resistance. Pathol. Res. Pract., 2020, 216(11) ,153215
[http://dx.doi.org/10.1016/j.prp.2020.153215] [PMID: 32979688]
[11]
Moran, V.A.; Perera, R.J.; Khalil, A.M. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res., 2012, 40(14), 6391-6400.
[http://dx.doi.org/10.1093/nar/gks296] [PMID: 22492512]
[12]
Bartonicek, N.; Maag, J.L.; Dinger, M.E. Long noncoding RNAs in cancer: Mechanisms of action and technological advancements. Mol. Cancer, 2016, 15(1), 43.
[http://dx.doi.org/10.1186/s12943-016-0530-6] [PMID: 27233618]
[13]
Sun, X.; Wang, Z.; Yuan, W. Down-regulated long non-coding RNA SNHG1 inhibits tumor genesis of colorectal carcinoma. Cancer Biomark., 2017, 20(1), 67-73.
[http://dx.doi.org/10.3233/CBM-170112] [PMID: 28759957]
[14]
Zhang, S-H.; Zhang, S-G.; Zhou, P.; Wei, X.; Mao, X-D.; Lin, S-G.; Liu, C. LncRNA MALAT1 affects high glucose-induced endothelial cell proliferation, apoptosis, migration and angiogenesis by regulating the pi3k/akt signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(19), 8551-8559.
[http://dx.doi.org/10.26355/eurrev_201910_19170]
[15]
Zhang, J-J.; Xu, W-R.; Chen, B.; Wang, Y-Y.; Yang, N.; Wang, L-J.; Zhang, Y-L. The up-regulated lncrna dlx6-as1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating pi3k/akt/mtor pathway. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(19), 8321-8331.
[http://dx.doi.org/10.26355/eurrev_201910_19143]
[16]
Yin, Q.; Shen, X.; Cui, X.; Ju, S. Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma. Exp. Hematol., 2019, 79, 47-55.e2.
[http://dx.doi.org/10.1016/j.exphem.2019.10.002] [PMID: 31647962]
[17]
Zhao, D.; Zhang, H.; Long, J.; Li, M. LncRNA SNHG7 Functions as an oncogene in cervical cancer by sponging mir-485-5p to modulate jund expression. OncoTargets Ther., 2020, 13, 1677-1689.
[http://dx.doi.org/10.2147/OTT.S237802] [PMID: 32161467]
[18]
Zhang, H.; Zhang, X.Y.; Kang, X.N.; Jin, L.J.; Wang, Z.Y. LncRNA-SNHG7 enhances chemotherapy resistance and cell viability of breast cancer cells by regulating miR-186. Cancer Manag. Res., 2020, 12, 10163-10172.
[http://dx.doi.org/10.2147/CMAR.S270328] [PMID: 33116871]
[19]
Hu, Y.; Wang, L.; Li, Z.; Wan, Z.; Shao, M.; Wu, S.; Wang, G. Potential prognostic and diagnostic values of CDC6, CDC45, ORC6 and SNHG7 in colorectal cancer. OncoTargets Ther., 2019, 12, 11609-11621.
[http://dx.doi.org/10.2147/OTT.S231941] [PMID: 32021241]
[20]
Zhang, L.; Fu, Y.; Guo, H. c-Myc-induced long non-coding RNA small nucleolar RNA host gene 7 regulates glycolysis in breast cancer. J. Breast Cancer, 2019, 22(4), 533-547.
[http://dx.doi.org/10.4048/jbc.2019.22.e54] [PMID: 31897328]
[21]
Zhang, Y.; Yuan, Y.; Zhang, Y.; Cheng, L.; Zhou, X.; Chen, K. SNHG7 accelerates cell migration and invasion through regulating miR-34a-Snail-EMT axis in gastric cancer. Cell Cycle, 2020, 19(1), 142-152.
[http://dx.doi.org/10.1080/15384101.2019.1699753] [PMID: 31814518]
[22]
Zeng, J.; Ma, Y.X.; Liu, Z.H.; Zeng, Y.L. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(21), 9277-9285.
[PMID: 31773679]
[23]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7) ,e1000097
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[24]
Lo, C.K.; Mertz, D.; Loeb, M. Newcastle-Ottawa Scale: Comparing reviewers’ to authors’ assessments. BMC Med. Res. Methodol., 2014, 14, 45.
[http://dx.doi.org/10.1186/1471-2288-14-45] [PMID: 24690082]
[25]
Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8, 16.
[http://dx.doi.org/10.1186/1745-6215-8-16] [PMID: 17555582]
[26]
Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ, 1997, 315(7109), 629-634.
[http://dx.doi.org/10.1136/bmj.315.7109.629]]
[27]
Shen, A.; Ma, J.; Hu, X.; Cui, X. High expression of lncRNA-SNHG7 is associated with poor prognosis in hepatocellular carcinoma. Oncol. Lett., 2020, 19(6), 3959-3963.
[http://dx.doi.org/10.3892/ol.2020.11490] [PMID: 32382340]
[28]
Qi, H; Wen, B; Wu, Q; Cheng, W; Lou, J; Wei, J; Huang, J; Yao, X Weng, G Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503. Biomed. & pharmacoth. =, 2018, 102, 326-332.
[http://dx.doi.org/10.1016/j.biopha.2018.03.011]
[29]
Zhang, P.; Shi, L.; Song, L.; Long, Y.; Yuan, K.; Ding, W.; Deng, L. LncRNA CRNDE and lncRNA SNHG7 are promising biomarkers for prognosis in synchronous colorectal liver metastasis following hepatectomy. Cancer Manag. Res., 2020, 12, 1681-1692.
[http://dx.doi.org/10.2147/CMAR.S233147] [PMID: 32210611]
[30]
Xia, Q.; Li, J.; Yang, Z.; Zhang, D.; Tian, J.; Gu, B. Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine (Baltimore), 2020, 99(7) ,e18993
[http://dx.doi.org/10.1097/MD.0000000000018993] [PMID: 32049793]
[31]
Li, Y.; Zeng, C.; Hu, J.; Pan, Y.; Shan, Y.; Liu, B.; Jia, L. Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression. J. Hematol. Oncol., 2018, 11(1), 89.
[http://dx.doi.org/10.1186/s13045-018-0632-2] [PMID: 29970122]
[32]
Shan, Y.; Ma, J.; Pan, Y.; Hu, J.; Liu, B.; Jia, L. LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. Cell Death Dis., 2018, 9(7), 722.
[http://dx.doi.org/10.1038/s41419-018-0759-7] [PMID: 29915311]
[33]
Wu, F.; Sui, Y.; Wang, Y.; Xu, T.; Fan, L.; Zhu, H. Long noncoding RNA SNHG7, a molecular sponge for microRNA-485, Promotes the aggressive behavior of cervical cancer by regulating PAK4. OncoTargets Ther., 2020, 13, 685-699.
[http://dx.doi.org/10.2147/OTT.S232542] [PMID: 32158221]
[34]
Cheng, D.; Fan, J.; Ma, Y.; Zhou, Y.; Qin, K.; Shi, M.; Yang, J. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Cell Biosci., 2019, 9, 28.
[http://dx.doi.org/10.1186/s13578-019-0290-2] [PMID: 30949340]
[35]
Wu, P.; Tang, Y.; Fang, X.; Xie, C.; Zeng, J.; Wang, W.; Zhao, S. Metformin suppresses hypopharyngeal cancer growth by epigenetically silencing long non-coding RNA SNHG7 in FaDu cells. Front. Pharmacol., 2019, 10, 143.
[http://dx.doi.org/10.3389/fphar.2019.00143] [PMID: 30853913]
[36]
Chi, R.; Chen, X.; Liu, M.; Zhang, H.; Li, F.; Fan, X.; Wang, W.; Lu, H. Role of SNHG7-miR-653-5p-STAT2 feedback loop in regulating neuroblastoma progression. J. Cell. Physiol., 2019, 234(8), 13403-13412.
[http://dx.doi.org/10.1002/jcp.28017] [PMID: 30623419]
[37]
Luo, X.; Song, Y.; Tang, L.; Sun, D.H.; Ji, D.G. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(22), 7788-7797.
[PMID: 30536320]
[38]
Xu, C.; Zhou, J.; Wang, Y.; Wang, A.; Su, L.; Liu, S.; Kang, X. Inhibition of malignant human bladder cancer phenotypes through the down-regulation of the long non-coding RNA SNHG7. J. Cancer, 2019, 10(2), 539-546.
[http://dx.doi.org/10.7150/jca.25507] [PMID: 30719150]
[39]
RL, S.; KD, M. clinicians JAJCacjf: Cancer statistics., 2016, 66(1), 7-30.
[40]
YH, H.; MS, L.; YS, L.; HC, L.; JC, Y.; CH, L.; CS, W.; one, WZJP. Propofol-based total intravenous anesthesia did not improve survival compared to desflurane anesthesia in breast cancer surgery. 2019, 14(11), e0224728..
[41]
Dong, J.S.; Wu, B.; Jiang, B. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of renal cell cancer cells by downregulating CDKN1A. Eur. Rev. Med. Pharmacol. Sci., 2020, 24(14), 7556.
[PMID: 32744661]
[42]
Chen, Z.; He, M.; Chen, J.; Li, C.; Zhang, Q. Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer. Oncol. Lett., 2020, 20(1), 893-901.
[http://dx.doi.org/10.3892/ol.2020.11635] [PMID: 32566017]
[43]
Bai, Z.; Wu, Y.; Bai, S.; Yan, Y.; Kang, H.; Ma, W.; Zhang, J.; Gao, Y.; Hui, B.; Ma, H.; Li, R.; Zhang, X.; Ren, J. Long non-coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer. J. Cell. Mol. Med., 2020, 24(13), 7479-7489.
[http://dx.doi.org/10.1111/jcmm.15373] [PMID: 32420685]
[44]
Chen, Y.; Yuan, S.; Ning, T.; Xu, H.; Guan, B. SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression. Technol. Cancer Res. Treat., 2020, 19 ,1533033820945802
[http://dx.doi.org/10.1177/1533033820945802] [PMID: 32720593]
[45]
Wang, L.; Zhang, L.; Wang, L. SNHG7 Contributes to the Progression of Non-Small-Cell Lung Cancer via the SNHG7/miR-181a-5p/E2F7 Axis. Cancer Manag. Res., 2020, 12, 3211-3222.
[http://dx.doi.org/10.2147/CMAR.S240964] [PMID: 32440218]
[46]
Sun, X.; Huang, T.; Liu, Z.; Sun, M.; Luo, S. LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. Eur. J. Pharmacol., 2019, 856 ,172407
[http://dx.doi.org/10.1016/j.ejphar.2019.172407] [PMID: 31132353]
[47]
Chen, L.; Zhu, J.; Zhang, L.J. Long non-coding RNA small nucleolar RNA host gene 7 is upregulated and promotes cell proliferation in thyroid cancer. Oncol. Lett., 2019, 18(5), 4726-4734.
[http://dx.doi.org/10.3892/ol.2019.10782] [PMID: 31611982]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy